Imidazolidine Derivatives in Cancer Research: What is known? / Auvani Antunes da Silva Júnior, Marina Galdino da Rocha Pitta, Mardonny Bruno de Oliveira Chagas, Moacyr Jesus Barreto de Melo Rêgo, Michelle Melgarejo da Rosa, Maira Galdino da Rocha Pitta
It is well known that cancer is the second leading cause of death worldwide. Due to this fact, new results for the treatment of cancer are constantly being introduced and verified. Imidazolidine derivatives regulate cell cycle progression and DNA stability. Structurally, a heterocyclic nucleus favors a direct DNA interaction and therefore, control of the DNA replication process. This review aims not only to discuss the role of imidazolidines in cancer therapy but also explore the functionality of such agents in the future aspects of cancer prognosis and treatment. Convincing data from 1996 to 2021 has presented imidazolidine derivatives as a relevant therapeutic tool to modulate cancer progression and malignancy. Here we highlight these aspects in a variety of cell lines, cancer types, involving in vitro and in vivo techniques.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 22(2022), 7, Seite 6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
da Silva Júnior, Auvani Antunes [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (6 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011155159 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011155159 | ||
| 003 | DE-627 | ||
| 005 | 20231128154831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011155159 | ||
| 035 | |a (KFL)prod_DARH_.51EE514440B6A545B441C1FF3CAF99FE6F9D2B31 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a da Silva Júnior, Auvani Antunes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imidazolidine Derivatives in Cancer Research: What is known? |c Auvani Antunes da Silva Júnior, Marina Galdino da Rocha Pitta, Mardonny Bruno de Oliveira Chagas, Moacyr Jesus Barreto de Melo Rêgo, Michelle Melgarejo da Rosa, Maira Galdino da Rocha Pitta |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (6 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a It is well known that cancer is the second leading cause of death worldwide. Due to this fact, new results for the treatment of cancer are constantly being introduced and verified. Imidazolidine derivatives regulate cell cycle progression and DNA stability. Structurally, a heterocyclic nucleus favors a direct DNA interaction and therefore, control of the DNA replication process. This review aims not only to discuss the role of imidazolidines in cancer therapy but also explore the functionality of such agents in the future aspects of cancer prognosis and treatment. Convincing data from 1996 to 2021 has presented imidazolidine derivatives as a relevant therapeutic tool to modulate cancer progression and malignancy. Here we highlight these aspects in a variety of cell lines, cancer types, involving in vitro and in vivo techniques | ||
| 700 | 1 | |a da Rocha Pitta, Marina Galdino |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira Chagas, Mardonny Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a de Melo Rêgo, Moacyr Jesus Barreto |e verfasserin |4 aut | |
| 700 | 1 | |a da Rosa, Michelle Melgarejo |e verfasserin |4 aut | |
| 700 | 1 | |a da Rocha Pitta, Maira Galdino |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d Sharjah : Bentham Sc. Publ., 2006 |g 22(2022), 7, Seite 6 |h Online-Ressource |w (DE-627)KFL000006505 |w (DE-600)2253831-8 |w (DE-576)273890913 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:7 |g pages:6 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5206&volume=22&issue=7&spage=1272 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 7 |h 6 | ||